5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
| Molecular Weight | 435.88 |
| Formula | C19H18ClN3O5S |
| CAS Number | 865479-71-6 |
| Form | Solid |
| Solubility (25°C) | DMSO 30 mg/mL (ultrasonic) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Factor Xa Products |
|---|
| MK-2060
MK-2060 is a monoclonal antibody with dual activity to inhibit coagulation factors XI and Xia, blocking both the activation of coagulation factor XI and the downstream activity of the activated protein. It can be used in studies related to end-stage renal disease (ESRD). |
| Xisomab 3G3
Xisomab 3G3 is a recombinant human-derived monoclonal antibody to coagulation factor XI (F11) that blocks factor XI activation mediated by factor XIIa in a concentration-dependent manner. |
| FXIa-IN-13
FXIa-IN-13 is an Factor Xa inhibitor with antithrombotic activity. |
| EMD 495235
EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. |
| Frunexian
Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
